Skip to main content
. 2014 Jul 30;8(4):1470–1476. doi: 10.3892/ol.2014.2396

Figure 3.

Figure 3

Kaplan-Meier curves of overall survival in NSCLC patients. (A) The 5-year overall survival rates were 55.0 and 24.3% in the patients with NSCLC with NEK2-negative expression (n=200) and NEK2-positive expression (n=70). (B) The 5-year overall survival rates were 56.6 and 29.5% in the patients with NSCLC with Mcm7-negative expression (n=175) and Mcm7-positive expression (n=95). (C) The 5-year overall survival rates were 53.4 and 27.3% in the patients with NSCLC with Ki67-negative expression (n=204) and Ki67-positive expression (n=66). (D) The 5-year overall survival rates were 59.5, 39.1 and 18.8% in the patients with NSCLC with NEK2- and Mcm7-negative expression (n=153), NEK2- or Mcm7-positive expression (n=69), and NEK2- and Mcm7-positive expression (n=48). (E) The 5-year overall survival rates were 57.8, 37.5 and 12.5% in the patients with NSCLC with NEK2- and Ki67-negative expression (n=166), NEK2- or Ki67-positive expression (n=72), and NEK2- and Mcm7-positive expression (n=32). (F) The 5-year overall survival rates were 63.1, 37.7 and 7.7% in the patients with NSCLC with NEK2-, Mcm7- and Ki67-negative expression (n=130), NEK2-, Mcm7- or Ki67-positive expression (n=114) and NEK2-, Mcm7- and Ki67-positive expression (n=26). There were significant differences between NEK2- and Mcm7/Ki67-positive, NEK2- or Mcm7/Ki67-positive, and NEK2- and Mcm7/Ki67-negative expression groups (P<0.0001).